-
Mashup Score: 2ASH 2022 abstracts: What’s hot in acute myeloid leukemia? - 1 year(s) ago
To help navigate the exciting content being presented at ASH 2022, the AML Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in AML.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 15“Blasts” in myeloid neoplasms – how do we define blasts and how do we incorporate them into diagnostic schema moving forward? - 2 year(s) ago
Leukemia –
“Blasts” in myeloid neoplasms – how do we define blasts and how… Source: www.nature.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“Blasts” in myeloid neoplasms – how do we define blasts and how do we incorporate them into diagnostic schema moving forward? Read for free using #SharedIt: https://t.co/C4Iercyblc #Acutemyeloidleukaemia #Myelodysplasticsyndrome https://t.co/7YlKSyo9Wj
-
-
Mashup Score: 1
Leukemia –
Improved relative survival in older patients with acute myeloid leukemia over a 30-year period… Source: www.nature.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in the Netherlands: a long haul is needed to change nothing into something Read for free with #SharedIt: https://t.co/pUdqePwq0Z #Acutemyeloidleukaemia #Cancerepidemiology https://t.co/ZOadaCRepC
-
-
Mashup Score: 1Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia - 2 year(s) ago
Mutations in isocitrate dehydrogenase 2 (IDH2) have been noted to impact cellular differentiation in addition to DNA and histone methylation. However, little is known about the impact of IDH2 mutations on intracellular signaling. Using an isogenic cell line model, we investigated both differentiation and signaling responses in IDH2 mutant cells and show augmented responses to inflammatory immune…
Source: www.nature.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia Read for free with #SharedIt: https://t.co/07TxhEWIIl #Acutemyeloidleukaemia #Cancergenetics #Cellsignalling https://t.co/yb8I7mEhCE
-
-
Mashup Score: 2Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia - 2 year(s) ago
Cord blood transplantation (CBT) is an alternative donor transplantation method and has the advantages of rapid availability and the possibility of inducing a more potent graft-versus-leukemia effect, leading to a lower relapse rate for patients with non-remission relapse and refractory acute myeloid leukemia (R/R AML). This study aimed to investigate the impact of CBT, compared to human…
Source: www.nature.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia Read for free with #SharedIt: https://t.co/bkScsZNbWU #Acutemyeloidleukaemia #Diseasefreesurvival https://t.co/4EPjPI3cGG
-
-
Mashup Score: 5The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML - Leukemia - 2 year(s) ago
FLT3-ITD is the most predominant mutation in AML being expressed in about one-third of AML patients and is associated with a poor prognosis. Efforts to better understand FLT3-ITD downstream signaling to possibly improve therapy response are needed. We have previously described FLT3-ITD-dependent phosphorylation of CSF2RB, the common receptor beta chain of IL-3, IL-5, and GM-CSF, and therefore…
Source: LeukemiaCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML Read for free: https://t.co/qnMK3MsisG #Oncogenesis #Translationalresearch #Acutemyeloidleukaemia https://t.co/0CS20g2I1g
-
-
Mashup Score: 5Whole-Genome Sequencing Provides Rapid and Accurate Genomic Profiling in Patients with AML or MDS - 3 year(s) ago
Clinical utility of whole-genome sequencing demonstrated for the genomic evaluation of patients with acute myeloid leukaemia or myelodysplastic…
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Whole-Genome Sequencing Provides Rapid and Accurate #GenomicProfiling in Patients with #acutemyeloidleukaemia or #myelodysplasticsyndromes https://t.co/B7Tsn9wTS9 @WUSTLmed #leusm https://t.co/bwbAeFOBae
-
-
Mashup Score: 0
It is intended for first-line treatment of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive type of acute myeloid leukaemia
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
EMA Recommends Marketing Authorisation for Tagraxofusp: intended for first-line treatment of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive type of #acutemyeloidleukaemia https://t.co/Jf69zX12ls #leusm https://t.co/EgNGMm2ycf
-
-
Mashup Score: 0The Cancer News Daily - 4 year(s) ago
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Cancer News Daily! https://t.co/CP1PmTAaBX Thanks to @Aiims1742 @myESMO #acutemyeloidleukaemia #leusm
-
-
Mashup Score: 2FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukaemia - 4 year(s) ago
Efficacy was confirmed in VIALE-A and VIALE-C studies
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA grants regular approval to venetoclax in combination for untreated #acutemyeloidleukaemia: Efficacy was confirmed in VIALE-A and VIALE-C studies 👉https://t.co/nVIDhePyV4 #leusm #leukaemia https://t.co/abXGHyynMS
-
What are your top picks? Discover our list of top abstracts for the 64th @ASH_Hematology Annual Meeting and Exposition! The abstracts, selected by our steering committee, provide updates in #acutemyeloidleukaemia. Learn more: https://t.co/OFKs2gsSbW #ASH2022 #leusm https://t.co/fuFOOwPofM